SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 15.92 |
| Enterprise Value ($M) | 6.06 |
| Book Value ($M) | 9.52 |
| Book Value / Share | 0.94 |
| Price / Book | 1.67 |
| NCAV ($M) | 7.65 |
| NCAV / Share | 0.75 |
| Price / NCAV | 2.08 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.55 |
| Return on Assets (ROA) | -0.66 |
| Return on Equity (ROE) | -0.78 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.77 |
| Current Ratio | 4.77 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 11.58 |
| Assets | 13.46 |
| Liabilities | 3.93 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -17.88 |
| Net Income | -17.50 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Beore Dividends Basic | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -16.48 |
| Cash from Investing | -0.01 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 5,382 | 14,360 | 37.48 | |
| 759 | 2,067 | 36.72 | |
| 571 | 1,969 | 29.00 | |
| 12,838 | 27,358 | 46.93 | |
(click for more detail) |
|||
Financial data and stock pages provided by
Fintel.io